

Prof. Mark H. Wilcox

Biographical Sketch

Professor Mark Wilcox is a Consultant Microbiologist, Head of Microbiology, and Clinical Director of Pathology, at the Leeds Teaching Hospitals, Professor of Medical Microbiology at the University of Leeds, and is the Lead on *Clostridium difficile* for the Health Protection Agency in England.

Professor Wilcox is deputy Chair of the UK Department of Health's Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee and a member of the HPA's Programme Board on Healthcare Associated Infection & Antimicrobial Resistance. He is an advisor to the Department of Health in England on healthcare associated infections (HCAIs), the Technology Strategy Board on HCAI diagnostics, the UK Medicines and Healthcare products Regulatory Agency, the EPIC/NICE projects, the Health Technology Assessment (HTA) programme on Healthcare Associated Infection, the Wellcome Trust and the European Centre for Disease Control. He is a member of UK, European and US working groups on *Clostridium difficile* infection, and is on the Editorial Boards of the Journal of Hospital Infection and Infectious Diseases in Clinical Practice.

Professor Wilcox's research team's projects include several areas of healthcare associated infection, in particular *Clostridium difficile* infection, staphylococcal infection, and the clinical development of new antimicrobial agents. He has a track record of translational research, including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for 12 clinical trials of new anti-infective drugs, 1999-2010, and is currently carrying out multiple NIHR portfolio studies on healthcare associated infection topics. He has authored more than 290 papers and published a number of books and chapters. He is co-editor of *Antimicrobial Chemotherapy* (5th & 6th Eds, 2007 & 2012).